These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27998038)

  • 21. T-helper epitopes identified within the E6 transforming protein of cervical cancer-associated human papillomavirus type 16.
    Azoury-Ziadeh R; Herd K; Fernando GJ; Frazer IH; Tindle RW
    Viral Immunol; 1999; 12(4):297-312. PubMed ID: 10630789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of promiscuous HPV16-derived T helper cell epitopes for therapeutic HPV vaccine design.
    Grabowska AK; Kaufmann AM; Riemer AB
    Int J Cancer; 2015 Jan; 136(1):212-24. PubMed ID: 24824905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of variants and therapeutic epitopes in HPV-33/HPV-58 E6 and E7 in Southwest China.
    He J; Yang Y; Chen Z; Liu Y; Bao S; Zhao Y; Ding X
    Virol J; 2019 May; 16(1):72. PubMed ID: 31138240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor Antigens beyond the Human Exome.
    Emilius L; Bremm F; Binder AK; Schaft N; Dörrie J
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FBXW7 is involved in the acquisition of the malignant phenotype in epithelial ovarian tumors.
    Kitade S; Onoyama I; Kobayashi H; Yagi H; Yoshida S; Kato M; Tsunematsu R; Asanoma K; Sonoda K; Wake N; Hata K; Nakayama KI; Kato K
    Cancer Sci; 2016 Oct; 107(10):1399-1405. PubMed ID: 27486687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FBXW7 mutations in melanoma and a new therapeutic paradigm.
    Aydin IT; Melamed RD; Adams SJ; Castillo-Martin M; Demir A; Bryk D; Brunner G; Cordon-Cardo C; Osman I; Rabadan R; Celebi JT
    J Natl Cancer Inst; 2014 Jun; 106(6):dju107. PubMed ID: 24838835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.
    Jardim DL; Wheler JJ; Hess K; Tsimberidou AM; Zinner R; Janku F; Subbiah V; Naing A; Piha-Paul SA; Westin SN; Roy-Chowdhuri S; Meric-Bernstam F; Hong DS
    PLoS One; 2014; 9(2):e89388. PubMed ID: 24586741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic profiles of cervical tumors by high-throughput sequencing for personalized medical care.
    Muller E; Brault B; Holmes A; Legros A; Jeannot E; Campitelli M; Rousselin A; Goardon N; Frébourg T; Krieger S; Crouet H; Nicolas A; Sastre X; Vaur D; Castéra L
    Cancer Med; 2015 Oct; 4(10):1484-93. PubMed ID: 26155992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identifying Comprehensive Genomic Alterations and Potential Neoantigens for Cervical Cancer Immunotherapy in a Cohort of Chinese Squamous Cell Carcinoma of the Cervix.
    Wu M; Zhou JL; Zhang Z; Meng YG
    Biomed Environ Sci; 2024 Jun; 37(6):565-580. PubMed ID: 38988108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Somatic Host Cell Alterations in HPV Carcinogenesis.
    Litwin TR; Clarke MA; Dean M; Wentzensen N
    Viruses; 2017 Aug; 9(8):. PubMed ID: 28771191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The genetic variability, phylogeny and functional significance of E6, E7 and LCR in human papillomavirus type 52 isolates in Sichuan, China.
    Song Z; Cui Y; Li Q; Deng J; Ding X; He J; Liu Y; Ju Z; Fang L
    Virol J; 2021 May; 18(1):94. PubMed ID: 33941222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of human papillomavirus-16 E6 variation in cervical cancer and their impact on T and B cell epitopes.
    Kumar A; Hussain S; Yadav IS; Gissmann L; Natarajan K; Das BC; Bharadwaj M
    J Virol Methods; 2015 Jun; 218():51-8. PubMed ID: 25800725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.
    Williams RD; Al-Saadi R; Chagtai T; Popov S; Messahel B; Sebire N; Gessler M; Wegert J; Graf N; Leuschner I; Hubank M; Jones C; Vujanic G; Pritchard-Jones K; ;
    Clin Cancer Res; 2010 Apr; 16(7):2036-45. PubMed ID: 20332316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human leukocyte antigen-DRB1*1501 and DQB1*0602 alleles are cervical cancer protective factors among Uighur and Han people in Xinjiang, China.
    Hu JM; Sun Q; Li L; Liu CX; Chen YZ; Zou H; Pang LJ; Zhao J; Yang L; Cao YW; Cui XB; Qi Y; Liang WH; Zhang WJ; Li F
    Int J Clin Exp Pathol; 2014; 7(9):6165-71. PubMed ID: 25337265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between HLA-DRB1 polymorphism, high-risk HPV infection and cervical neoplasia in southern Chinese.
    Chan PK; Cheung TH; Lin CK; Siu SS; Yim SF; Lo KW; Cheung JL; Tam AO; Tang JW
    J Med Virol; 2007 Jul; 79(7):970-6. PubMed ID: 17516530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of the impact on T- and B- cell epitopes of human papillomavirus type-16 E6 and E7 variant in Southwest China.
    Chenzhang Y; Wen Q; Ding X; Cao M; Chen Z; Mu X; Wang T
    Immunol Lett; 2017 Jan; 181():26-30. PubMed ID: 27693214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fbxw7 hotspot mutations and human colon cancer: mechanistic insights from new mouse models.
    Grim JE
    Gut; 2014 May; 63(5):707-9. PubMed ID: 24000292
    [No Abstract]   [Full Text] [Related]  

  • 38. FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias.
    Song JH; Schnittke N; Zaat A; Walsh CS; Miller CW
    Leuk Res; 2008 Nov; 32(11):1751-5. PubMed ID: 18485478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genome-Wide Profiling of Human Papillomavirus DNA Integration into Human Genome and Its Influence on PD-L1 Expression in Chinese Uygur Cervical Cancer Women.
    Yang-Chun F; Sen-Yu W; Yuan Z; Yan-Chun H
    J Immunol Res; 2020; 2020():6284960. PubMed ID: 32411801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antigenic Peptide Prediction From E6 and E7 Oncoproteins of HPV Types 16 and 18 for Therapeutic Vaccine Design Using Immunoinformatics and MD Simulation Analysis.
    Jabbar B; Rafique S; Salo-Ahen OMH; Ali A; Munir M; Idrees M; Mirza MU; Vanmeert M; Shah SZ; Jabbar I; Rana MA
    Front Immunol; 2018; 9():3000. PubMed ID: 30619353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.